Clinical Trials

A Phase 3 clinical trial sponsored by Incyte Corporation evaluated oral administration of a Janus kinase inhibitor in patients with myeloproliferative neoplasms, specifically primary myelofibrosis. This randomized, double-blind, placebo-controlled investigation has completed recruitment. Altogether, the study reflects the advanced late-stage evaluation of targeted Janus kinase pathway inhibition for therapeutic management of these conditions.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00952289 COMPLETED
MPN (Myeloproliferative Neoplasms)
Incyte Corporation
 2009-08 PHASE3

(data from https://clinicaltrials.gov, updated on 2018-03-12)

Check the Pyridone 6 product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Pyridone 6 acts as a potent pan-Janus kinase inhibitor that binds directly to the ATP-binding domains of JAK1, JAK2, JAK3, and TYK2, thereby blocking STAT protein phosphorylation and disrupting downstream cytokine-mediated signaling cascades. By inhibiting these intracellular pathways, the compound suppresses abnormal cell proliferation and survival, which directly addresses the pathological driver mechanisms underlying myeloproliferative neoplasms.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.